All In Biotech

Drug Trial Radar · NCT06208410

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

306

Planned (sponsor's estimate)

Start

Jan 11, 2024

Primary completion

Feb 26, 2027

Study completion Feb 26, 2027

Sponsor

Sponsor type
Industry
First posted
Jan 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multicenter, Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS105 in combination with other anti-tumor therapies in patients with advanced solid tumors. Patients will be enrolled in two stages: a dose-escalation stage and a dose-expansion stage.

Conditions

  • Advanced Solid Tumors

Interventions

  • JS105Drug

    JS105 is administered once daily, orally

  • Fulvestrant injectionDrug

    Fulvestrant intramuscularly,The first cycle was injected once in D1 and D15, and then once in each cycle D1, and 28 days was 1 cycle

  • Dalpiciclib Isetionate TabletsDrug

    Dalpiciclib Isetionate Tablets, QD, oral, taken continuously for 21 days, then stopped for 7 days, 28 days for a cycle

  • Toripalimab InjectionDrug

    Toripalimab Injection,Intravenous infusion, once every 3 weeks, 21 days for 1 cycle

  • Paclitaxel for Injection (Albumin Bound)Drug

    Paclitaxel for Injection (Albumin Bound),Intravenous infusion, D1, 8, 15 infusion, every 28 days for a cycle

  • Fluzoparib CapsulesDrug

    Fluzoparib Capsules is administered once daily, orally

  • Pyrotinib Maleate TabletsDrug

    Pyrotinib Maleate Tablets is administered once daily, orally

  • Capecitabine TabletsDrug

    Capecitabine Tablets is administered once daily, orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicityTime frame: At the end of Cycle 1 (each cycle is 28 days)
  2. MTDTime frame: At the end of Cycle 1 (each cycle is 28 days)
  3. RP2DTime frame: At the end of Cycle 1 (each cycle is 28 days)
  4. Incidence and severity of adverse events including serious adverse eventsTime frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Provincial Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.